Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.

Publication ,  Journal Article
Nicholson, HS; Kretschmar, CS; Krailo, M; Bernstein, M; Kadota, R; Fort, D; Friedman, H; Harris, MB; Tedeschi-Blok, N; Mazewski, C; Sato, J ...
Published in: Cancer
October 1, 2007

BACKGROUND: Effective chemotherapy is lacking for most types of central nervous system (CNS) tumors in children. Temozolomide, an agent with activity against adult brain tumors, was investigated in children and adolescents with recurrent CNS tumors. METHODS: Temozolomide was administered orally as monthly 5-day courses at doses of 200 mg/m(2)/d (patients with no prior craniospinal irradiation [CSI]) or 180 mg/m(2)/d (prior CSI). Patients with a complete (CR) or partial (PR) response or stable disease (SD) could continue temozolomide for up to 12 cycles. RESULTS: The cohort comprised 122 patients, including 113 with CNS tumors. Median age was 11 years (range, 1-23 years). Among 104 evaluable patients with CNS tumors, 5 PRs and 1 CR were observed. PRs occurred in 1 of 23 evaluable patients with high-grade astrocytoma, 1 of 21 with low-grade astrocytoma, and 3 of 25 with medulloblastoma/primitive neuroectodermal tumor (PNET). The CR occurred in an additional patient with medulloblastoma/PNET. No responses were observed in patients with ependymoma, brain-stem glioma, or other CNS tumors. Notably, 41% of patients with low-grade astrocytoma had SD through 12 courses. The most frequent toxicities were grade 3 or 4 neutropenia (19%) and thrombocytopenia (25%); nonhematologic toxicity was infrequent. CONCLUSIONS: Although overall objective responses were limited, further exploration of temozolomide may be warranted in children with medulloblastoma and other PNETs, or in patients with low-grade astrocytoma, perhaps in a setting of less pretreatment than the patients in the current study, or in the context of multiagent therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

October 1, 2007

Volume

110

Issue

7

Start / End Page

1542 / 1550

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Temozolomide
  • Oncology & Carcinogenesis
  • Neuroectodermal Tumors, Primitive
  • Neoplasm Recurrence, Local
  • Medulloblastoma
  • Male
  • Infant
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nicholson, H. S., Kretschmar, C. S., Krailo, M., Bernstein, M., Kadota, R., Fort, D., … Reaman, G. H. (2007). Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer, 110(7), 1542–1550. https://doi.org/10.1002/cncr.22961
Nicholson, H Stacy, Cynthia S. Kretschmar, Mark Krailo, Mark Bernstein, Richard Kadota, Daniel Fort, Henry Friedman, et al. “Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.Cancer 110, no. 7 (October 1, 2007): 1542–50. https://doi.org/10.1002/cncr.22961.
Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542–50.
Nicholson, H. Stacy, et al. “Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.Cancer, vol. 110, no. 7, Oct. 2007, pp. 1542–50. Pubmed, doi:10.1002/cncr.22961.
Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542–1550.
Journal cover image

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

October 1, 2007

Volume

110

Issue

7

Start / End Page

1542 / 1550

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Temozolomide
  • Oncology & Carcinogenesis
  • Neuroectodermal Tumors, Primitive
  • Neoplasm Recurrence, Local
  • Medulloblastoma
  • Male
  • Infant
  • Humans
  • Female